Valneva SE

Regulatory Filings • Apr 23, 2010

.

VIVALIS ANNONCES THE FILING OF ITS ANNUAL REGISTRATION DOCUMENT

Nantes (France) – April, 23 2010 − VIVALIS, a biopharmaceutical company, announces the filing of its Registration Document under the number R.10-026 dated April 22nd, 2010, with the Autorité des marchés Financiers (« AMF »).

The registration document is available free of charge at VIVALIS' head office, 6, rue Alain Bombard, 44821 Saint-Herblain cedex, FRANCE and in electronic form on the company's web site (www.vivalis.com) and on the web site of the AMF (www.amf-france.org).

*******************

Next financial press release:

May 4, 2010, after NYSE Euronext market closing: 2010 first-quarter sales

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions for the manufacture of vaccines and proteins, and develops therapeutics for unmet diseases. VIVALIS'S expertise and intellectual property are leveraged in three principal areas:

1. VIVALIS offers research and commercial licenses for its EB66® Cell Line, which is derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of vaccines and monoclonal antibodies. VIVALIS receives upfront fees, milestone payments and royalties on licensees' net sales.

2. Through the Humalex® platform, VIVALIS provides solutions for the generation, development and production of human therapeutic antibodies. VIVALIS receives upfront fees, milestone payments and royalties on licensees' net sales.

3. The development of a portfolio of proprietary monoclonal antibodies and anti-viral molecules (e.g., Hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud Group (1,500 employees), the second largest worldwide corporation in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in biotherapeutics, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Contacts

VIVALIS NewCap

Franck Grimaud, CEO Financial communications agency Email: investors@vivalis.com Steve Grobet / Emmanuel Huynh Tel.: +33 (0) 1 44 71 94 91 Email: vivalis@newcap.fr